Asgard Therapeutics to present new preclinical data on AT‑108 at ASGCT 2026

28th April 2026 Uncategorised 0

Lead asset shows systemic, dose‑dependent anti‑tumour activity

More: Asgard Therapeutics to present new preclinical data on AT‑108 at ASGCT 2026
Source: News